Replies to post #335 on Otonomy Inc. fka OTIC

[TheFinalCD]

well was $20+ before the p3 fail in the US, should be worth at least half that= $10 with the new Data, even if Europe...right :-)

OTIC


52w range= 2.80-$21.15

current pps= 5.60

I like our chances:-D

“The success of the AVERTS-2 trial clearly demonstrates the treatment benefit of OTIVIDEX in patients with Ménière’s disease, and these results are consistent with our expectations based on the Phase 2b trial," said David A. Weber, Ph.D., president and CEO of Otonomy. “We will complete analysis of this trial and prepare for discussions with the FDA which we expect to occur during the first quarter of 2018.

We will also further assess the AVERTS-1 trial to identify factors that might explain the different outcome in that trial and inform the design of our clinical program to support an NDA filing."